Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of PBP1510 in Advanced/Metastatic Pancreatic Cancer
2024-514379-16-00Phase 2Authorised
- Sponsor
- Prestige Biopharma Limited
- Start
- Oct 2024
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label trial of ulenistamab in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Prestige Biopharma Limited. Primary endpoints: Safety and tolerability of PBP1510 (Phase 1), Safety of PBP1510 at RP2D in combination with gemcitabine (Phase 2a) and 1 more. Planned start Oct 2024; status: authorised.
02
Drugs
ulenistamab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-514379-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514379-16-00.